{"id":269582,"date":"2026-09-25T09:50:09","date_gmt":"2026-09-25T04:20:09","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=269582"},"modified":"2026-09-25T09:50:09","modified_gmt":"2026-09-25T04:20:09","slug":"marksans-pharma-vs-jubilant-pharmova-vs-granules-india","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/marksans-pharma-vs-jubilant-pharmova-vs-granules-india\/","title":{"rendered":"Marksans Pharma vs Jubilant Pharmova vs Granules India: Which Stock Should You Track"},"content":{"rendered":"

Marksans Pharma PE 29.36, mkt cap Rs 15,299 crore. Jubilant Pharmova PE 48.21, mkt cap Rs 16,941 crore. Granules India PE 35.15, mkt cap Rs 23,282 crore.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Marksans Pharma vs Jubilant Pharmova vs Granules India is a side-by-side comparison of three companies from the Generic and Formulation Pharma space. On this comparison, Marksans Pharma carries a market capitalisation of about Rs 15,299 crore against Rs 16,941 crore for Jubilant Pharmova and Rs 23,282 crore for Granules India, with return on equity of 13.82%, 5.62% and 11.70% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.<\/p>\n<\/div>\n

Marksans Pharma vs Jubilant Pharmova vs Granules India starts with the core numbers most investors compare within the Generic and Formulation Pharma segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.<\/p>\n

All three names sit in the Generic and Formulation Pharma bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n